Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that ...

The FDA's assessment of the bread recall has designated it as a Class II risk, which means the product "may cause temporary ...

Coca-Cola is making a version with cane sugar instead of high-fructose corn syrup. Here’s what research says about its health ...

FDA fast-tracks DB-1310, a novel HER3-targeting ADC, offering hope for advanced NSCLC patients with unmet treatment needs.

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Trump celebrated when the Supreme Court limited nationwide blocks on his policies, but judges are finding other ways to ...

BMO Capital Markets pointed to FDA leadership, and CBER Director Vinay Prasad in particular, as potential factors in the ...

A combination of two cancer drugs may provide a pathway to treat Alzheimer’s, according to a study published July 21 in Cell.  Researchers from the University of California San Francisco developed and ...

Nearly 5 months after several companies voluntarily agreed to recall select acne products due to elevated benzene levels, uncertainty remains regarding any clinical risk with the formulations that ...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 11 Best All-Time Low Stocks to Buy According to Analysts. On July ...

From cell-manufacturing laboratories to outpatient infusion facilities, health systems are rapidly adapting to a new kind of cancer treatment that demands individualized care, infrastructure and ...

Novo Nordisk holds 72% international and 50%+ U.S. market share in GLP-1 treatments, serving 46 million patients globally.